The risk for bleeding during antithrombotic therapy for atrial fibrillation can be determined based on a number of clinical factors identified by the NCCCC as funded by NICE in the United Kingdom.
Patient selection: atrial fibrillation on warfarin/coumadin
Parameters:
(1) age of the patient in years
(2) therapy with antiplatelet drugs (aspirin or glycoprotein IIb/IIIa receptor antagonist) or NSAID
(3) uncontrolled hypertension
(4) history of bleeding or intracerebral hemorrhage (ICH)
(5) anemia
(6) polypharmacy (multiple other medications)
(7) control of anticoagulation therapy
Parameter |
Finding |
Points |
---|---|---|
age of the patient |
<= 75 years of age |
0 |
|
> 75 years of age |
1 |
therapy with antiplatelet drugs |
no |
0 |
|
yes |
1 |
uncontrolled hypertension |
absent |
0 |
|
present |
1 |
history of bleeding |
absent |
0 |
|
present |
1 |
anemia |
absent |
0 |
|
present |
1 |
polypharmacy |
absent |
0 |
|
present |
1 |
control of anticoagulation therapy |
fair to good |
0 |
|
poor |
1 |
where:
• A history of bleeding can be assigned a higher point value because of increased risk.
• The impact of antiplatelet drugs and NSAIDS is affected by dose and other factors.
total number of risk factors =
= SUM(points for all 7 parameters)
Interpretation:
• minimum number of risk factors: 0
• maximum number of risk factors: 7
• The greater the number of risk factors the greater the risk of bleeding.
Purpose: To identify risk factors for bleeding in a patient taking oral anticoagulant therapy for atrial fibrillation based on the NICE guidelines.
Specialty: Hematology Oncology, Clinical Laboratory, Pharmacology, clinical
Objective: risk factors, severity, prognosis, stage
ICD-10: I48,